BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib

British Journal of Cancer

Volumn 107, Issue 6, 2012, Pages 947-955

  Godinho, M F E ^a   Wulfkuhle, J D ^b   Look, M P ^a   Sieuwerts, A M ^a   Sleijfer, S ^a   Foekens, J A ^a   Petricoin, E F ^b   Dorssers, L C J ^a   Van Agthoven, T ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

BCAR4; breast cancer; ERBB2; tamoxifen resistance; targeted therapy

Indexed keywords

AFIMOXIFENE; ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FOCAL ADHESION KINASE; FULVESTRANT; IFOSFAMIDE; LAPATINIB; MESSENGER RNA; METHOTREXATE; PROTEIN KINASE B; PROTEIN SHC; STAT5 PROTEIN; STAT6 PROTEIN; TAMOXIFEN;

ARTICLE; BCAR4 GENE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SENSITIZATION; ERBB2 GENE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE; GENE EXPRESSION; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, UNTRANSLATED; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84865864136     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.351     Document Type: Article

References (45)

1. Barone I, Brusco L, Fuqua SA (2010) Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 16(10): 2702-2708
2. Bates NP, Hurst HC (1997) An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene 15(4): 473-481
3. Brinkman A, Van der Flier S, Kok EM, Dorssers LCJ (2000) BCAR1, a human homologue of the adapter protein p130Cas and ntiestrogen resistance in breast cancer cells. J Natl Cancer Inst 92: 112-120
4. Burris 3rd HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23(23): 5305-5313
5. Carraway KL, Price-Schiavi SA, Komatsu M, Jepson S, Perez A, Carraway CA (2001) Muc4/sialomucin complex in the mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 6(3): 323-337
6. Carter AM (2007) Animal models of human placentation-a review. Placenta 28(Suppl A): S41-S47
7. Chu I, Blackwell K, Chen S, Slingerland J (2005) The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65(1): 18-25
8. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R (2008) Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 68(18): 7493-7501
9. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793): 771-784
10. Di Segni A, Farin K, Pinkas-Kramarski R (2008) Identification of nucleolin as new ErbB receptors-interacting protein. PLoS One 3(6): e2310
11. Dorssers LCJ, Veldscholte J (1997) Identification of a novel breast-canceranti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells. Int J Cancer 72: 700-705
12. Esteva FJ, Yu D, Hung MC, Hortobagyi GN (2010) Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 7(2): 98-107
13. Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE (2009) Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res 11(1): R11
14. Funes M, Miller JK, Lai C, Carraway 3rd KL, Sweeney C (2006) The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J Biol Chem 281(28): 19310-19319
15. Godinho M, Meijer D, Setyono-Han B, Dorssers LC, van Agthoven T (2011) Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells. J Cell Physiol 226: 1741-1749
16. Godinho MFE, Sieuwerts AM, Look MP, Meijer D, Foekens JA, Dorssers LCJ, van Agthoven T (2010) Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br J Cancer 103(8): 1284-1291
17. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23(11): 2469-2476
18. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M (2010) Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 121(1): 53-64
19. Johnston S, Pippen Jr J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27(33): 5538-5546
20. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumabtreated breast cancer cells. Cancer Res 66(3): 1630-1639
21. Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR (2010) Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 16(5): 1486-1497
22. Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, CarneyW(2005) Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104(2): 257-263
23. Malassine A, Frendo JL, Evain-Brion D (2003) A comparison of placental development and endocrine functions between the human and mouse model. Hum Reprod Update 9(6): 531-539
24. Massarweh S, Schiff R (2006) Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 13(Suppl 1): S15-S24
25. Massarweh S, Schiff R (2007) Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res 13(7): 1950-1954
26. Mayer IA, Arteaga CL (2010) Does lapatinib work against HER2-negative breast cancers? Clin Cancer Res 16(5): 1355-1357
27. Meijer D, Van Agthoven T, Bosma PT, Nooter K, Dorssers LCJ (2006) Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res 4: 379-386
28. Mochizuki S, Okada Y (2007) ADAMs in cancer cell proliferation and progression. Cancer Sci 95(5): 621-628
29. Munzone E, Curigliano G, Rocca A, Bonizzi G, Renne G, Goldhirsch A, Nole F (2006) Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 8(1): R4
30. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9): 631-643
31. Paik S, Kim C, Wolmark N (2008) HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358(13): 1409-1411
32. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH (2007) Pathways to tamoxifen resistance. Cancer Lett 256: 1-24
33. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon Y, Cajal S, Arribas J, Baselga J (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28(6): 803-814
34. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA (2005)How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 11(20): 7311-7321
35. Spector NL, Xia W, Burris 3rd H, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S (2005) Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23(11): 2502-2512
36. Tan M, Yu D (2007) Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol 608: 119-129
37. Van Agthoven T, Godinho MFE, Wulfkuhle JD, Petricoin III EF, Dorssers LCJ (2012) Protein pathway activation mapping reveals molecular networks associated with anti-estrogen resistance in breast cancer cell lines. Int J Cancer (in press)
38. Van Agthoven T, Sieuwerts AM, Meijer-Van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LCJ (2009) Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 27: 542-549
39. Van Agthoven T, Sieuwerts AM, Meijer D, Meijer-van Gelder ME, Van Agthoven TLA, Sarwari R, Sleijfer S, Foekens JA, Dorssers LCJ (2010) Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocr Relat Cancer 17: 215-230
40. Van Agthoven T, Van Agthoven TLA, Dekker A, Foekens JA, Dorssers LCJ (1994) Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol Endocrinol 8: 1474-1483
41. Van Agthoven T, Van Agthoven TLA, Dekker A, Van der Spek PJ, Vreede L, Dorssers LCJ (1998) Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17: 2799-2808
42. Van Agthoven T, Van Agthoven TLA, Portengen H, Foekens JA, Dorssers LCJ (1992) Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52: 5082-5088
43. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 103(20): 7795-7800
44. Xia W, Liu LH, Ho P, Spector NL (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23(3): 646-653
45. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G Alligood KJ, Spector NL (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21(41): 6255-6263